MedWatch

Sydbank positive despite muted growth for Darzalex

Partner J&J's interim report shows that sales of Genmab’s cancer drug Darzalex doubled in Q3. However, the growth rate is lower compared to earlier this year, whivh has caused a drop in Genmab's share price. But despite the cancer hope’s failure to meet expectations, Sydbank still calls the development positive.

Photo: Genmab, PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles